Merrimack Pharma

MACK NASDAQ
6.55
-0.02
-0.30%
Closed 16:00 08/16 EDT
Open
6.63
Prev Close
6.57
High
6.64
Low
6.49
Volume
13.45K
Avg Vol (3M)
60.94K
52 Week High
7.50
52 Week Low
3.340
% Turnover
0.10%
Market Cap
87.44M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Merrimack Pharma MACK stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Merrimack Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in designing novel treatments for cancer by targeting biomarker-defined cancers. Its clinical programs include MM-121 (seribantumab), MM-141 (istiratumab) and MM-310. MM-121 is a fully human monoclonal antibody that binds to the ErbB3 (HER3) receptor and targets heregulin positive cancers. MM-141 is a fully human tetravalent bispecific antibody designed to block tumor survival signals by targeting receptor complexes containing the insulin-like growth factor 1, or IGF-1, receptor and ErbB3 (HER3) cell surface receptor. MM-310 is an antibody-directed nanotherapeutic that targets the ephrin receptor A2, or EphA2, receptor and contains a novel prodrug of the highly potent chemotherapy docetaxel. The Company’s preclinical programs include MM-161, ATRi, BCL2/BCLxl, TRAIL, Immuno-oncology and STIMULI.
MORE >

Recently

Name
Price
%Change